Phrontline Biopharma
PrivateLast Round
pre_series_a_plus
Nov 25, 2025
Total Funding Raised
$60M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Phrontline Biopharma is a biotechnology company that develops innovative antibody-drug conjugates (ADCs) to address unmet medical needs in oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Phrontline Biopharma Comparables
Compare Phrontline Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allink Biotherapeutics | 88% | |
| Elikya Therapeutics | 85% | |
| Eli Lilly and Company | 84% |
Phrontline Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| pre_series_a_plus | Nov 25, 2025 | ||||
| Early Funding | Nov 21, 2025 | ||||
| VC Round | Dec 25, 2023 | ||||
| Angel | Mar 10, 2022 |
Phrontline Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jifeng Ventures | Early Funding, pre_series_a_plus |
| Lapam Capital | pre_series_a_plus |
| Samsung Venture Investment | Early Funding, pre_series_a_plus |
| C&D Emerging Industry Equity Investment | pre_series_a_plus |
| Medfine Capital | VC Round, Angel, pre_series_a_plus |
| Samsung Venture Investment | pre_series_a_plus |
| Hankang Capital | pre_series_a_plus |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2026
Grew 100% QoQ from 5 to 10 employees.
- Nov 25, 2025
Raised $60M in a pre-Series A+ round.
Phrontline Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Phrontline Biopharma's valuation, stock price, and market status.
Is Phrontline Biopharma a public or private company?
Phrontline Biopharma is a private company.
What is the current stock price of Phrontline Biopharma?
Phrontline Biopharma is a private company with no public stock price. No recent secondary market data is available.
How much is Phrontline Biopharma worth (valuation)?
Valuation information for Phrontline Biopharma is not publicly available.
Can I buy Phrontline Biopharma stock?
Phrontline Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Phrontline Biopharma's last funding round?
Phrontline Biopharma's most recent funding round was pre_series_a_plus on November 25, 2025.
Who are the main investors in Phrontline Biopharma?
Key investors in Phrontline Biopharma include Lapam Capital.
Will Phrontline Biopharma IPO soon?
No public IPO plans have been announced for Phrontline Biopharma.
How can I track Phrontline Biopharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Phrontline Biopharma's secondary market activity and sign up for updates.